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HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH 
HEPATITIS A IN A US COMMERCIALLY INSURED POPULATION
Eisenberg D1, Changolkar A2, Misurski D2
1HealthCore, Wilmington, DE, USA; 2GSK, Philadelphia, PA, USA
OBJECTIVES: While the economic burden associated with acute hepatitis a outbreaks 
studied, the impact on health care utilization and associated cost has not been exam-
ined over one year in a commercially insured population. METHODS: An observa-
tional, retrospective study using HealthCore Integrated Research Database (HIRDSM) 
medical and pharmacy claims (January 1, 2004–December 31, 2009) was conducted. 
Index date was assigned based on the ﬁ rst medical claim for hepatitis a (intake period 
January 1, 2005—December 31, 2008). The control group did not have hepatitis. The 
index date assigned was of the hepatitis a match. Subjects had continuous plan eligibil-
ity for ≥12 months pre- and post-index. Descriptive statistics, including t-tests and 
chi-square analyses were used. RESULTS: Comparisons (n = 2331 for each cohort) 
were signiﬁ cant (p < 0.01). Post-index inpatient hospitalization occurred for 482 
(20.7%) hepatitis a patients and 193 (8.3%) controls. Associated mean costs (+SD) 
were $5,401 (+/−$30,567) and $1,929 (+/−$23,282), respectively. Emergency room 
(ER) services occurred in 382 (16.4%) hepatitis a subjects versus 277 (11.9%) con-
trols. Mean costs were $231 (+/−$816) and $139 (+/−$604), respectively. The mean 
number of outpatient services for the hepatitis a group was 21.5 (+/−22.1) versus 14.7 
(+/−18.2) for controls with associated mean costs of $4,985 (+/−$14,936) and $2,948 
(+/−$14,624), respectively. The mean number of physician visits were 9.1 (+/−9.9) and 
5.5 (+/−7.4) for each group, respectively [mean costs = $1185 (+/−$3712) and $675 
(+/−$2183)]. There were 20.13 (+/−24.1) and 19.37 (+/−24.5) pharmacy claims with 
mean costs of $2255 (+/−$5828) and $1420 (+/−$2656), in the hepatitis a and con-
trols. Mean total associated costs were $14,056 (+/−$42,666) and $7,111 (+/−
$30,519) in the hepatitis a and controls. CONCLUSIONS: In the 12-month post-index 
period hepatitis a patients had greater total health care utilization and costs compared 
to controls suggesting hepatitis a is associated with an increase in health care utiliza-
tion and costs.
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IMPACT OF YELLOW FEVER OUTBREAKS IN BRAZIL, 2000–2009
Ramos CG, Ferreira Da Silva AL
Universidade Federal do Rio Grande do Sol, Porto Alegre, Brazil
OBJECTIVES: To evaluate the health and economic impact of the expansion of YF 
virus in Brazil in the period of 2000–2009. METHODS: The perspective of study was 
the public health care system. We evaluated the direct costs of hospitalization and YF 
vaccine. Data source was the public ofﬁ cial national information on YF cases and YF 
vaccination from Brazilian Ministry of Health. We assumed that all cases required 
hospitalization and that all fatalities required intensive care unit (ICU) hospitalization 
and dialysis. All values were referent to December of 2009. The values of hospitaliza-
tion by yellow fever, ﬁ ve days ICU hospitalization and ﬁ ve days dialysis paid by public 
health system were, respectively, R$174.45 (c79.3); R$2393.60 (c1088) and R$ 557.1 
(c253.23). RESULTS: During the evaluated period, YF virus circulation was detected 
in eight states previously YF free. There were 320 cases of YF with lethality rate of 
46.5%. The cumulative population vaccinated was 90,906,675 individuals. The YF 
related hospitalization cost was R$ 495,478.30 (c225,217.41) and YF vaccine cost 
was R$89,997,608 (c40,908,003.75) within the 10 year period evaluated. CONCLU-
SIONS: Even in areas with susceptive population there were few cases of yellow fever. 
However, the signiﬁ cant clinical impact of the disease was due to its high lethality. 
Despite the severity of yellow fever, hospitalization costs were modest in the study 
period. The main cost was with the vaccine, the only form of prevention and control 
of disease. Thereby, it is necessary to evaluate the ﬁ nancial impact of vaccinating the 
areas that still have no evidence of the yellow fever virus, since there seems to be an 
expansion tendency of YF virus circulation to the country as a whole and the vaccina-
tion could prevent YF cases and deaths.
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A PILOT COST-OF-ILLNESS STUDY ON LONG TERM COMPLICATIONS/
SEQUELAE FOLLOWING ACUTE OTITIS MEDIA (AOM) IN BELGIUM
Strens D1, Dhooge I2, Knerer G3, Van Vlaenderen I1
1Deloitte, Diegem, Belgium; 2Ghent University Hospital, Ghent, Belgium; 3GlaxoSmithKline 
Biologicals, Wavre, Belgium
OBJECTIVES: A study was carried out to assess the economic burden associated with 
complications and/or long -term sequelae of AOM. This pilot study was done to assess 
feasibility to extend to a larger sample. METHODS: A retrospective patient chart 
review was performed in one Belgian center to obtain data on medical consumption 
related to the management of complications/sequelae of AOM. Data were collected 
for 10–15 years from the ﬁ rst AOM event onwards. Patients were eligible if they were 
between 10 and 20 years old with minimum 9 years of follow up data available and 
experienced a complication of AOM. Data on demographics, occurrence and type of 
complication, management of AOM, complications and sequelae were collected per 
year. Direct costs were calculated by multiplying each item of resource use with its 
unit cost (2010 in c) using the Belgian public health care payer’s perspective. Average 
(SD) yearly cost per patient, average yearly cost pre-complication, average cost during 
the year of complication, average yearly cost post-complication were calculated. 
RESULTS: Twenty-ﬁ ve patients were recruited in this pilot study. Complications were 
chronic suppurative OM with cholesteatoma, chronic perforation of the tympanic 
membrane and sensorineural hearing loss. The average yearly cost per patient was 
c966(SD:1579) with following components; hearing aid devices (c381(SD:1356)), 
hospitalizations (c298(SD:250)), outpatient procedures (c121(SD:107)), visits (c91 
(SD:183)), tests (c48(SD:46)) and drugs (c25(SD:89)). a complication occurred on 
average 5.3 years (SD: 2.9) after the ﬁ rst AOM event. Average annual cost pre-com-
plication was c232(SD:218), with outpatient procedures as main cost drivers. Average 
cost of complication per annum was c2808(SD:4827), average yearly cost post-
complication was c1593(SD:3366). As from occurrence of complication onwards costs 
are mainly driven by hospitalizations and hearing aid devices. CONCLUSIONS: Long 
term complications/sequelae of AOM result in considerable costs for the health care 
payer, mainly driven by hospitalizations, and hearing aid devices.
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HEPATITIS C BURDEN IN RUSSIA
Omelyanovsky VV, Avksentieva MV, Krysanov I, Ivakhnenko O
Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Moscow, 
Russia
OBJECTIVES: To assess social and economic burden of a hepatitis Ñ infection in 
Russian Federation. METHODS: Cost of illness analysis was performed. Available 
data on epidemiology of hepatitis C infection in Russian Federation has been analyzed. 
Experts were surveyed to describe common practice of treating patients with acute 
and chronic hepatitis C. Costs of medical care were calculated from the health care 
system point of view. RESULTS: State registration of hepatitis C infection has been 
launched in 1994. The incidence of acute hepatitis C is decreasing while there is 
increase in chronic hepatitis C new cases. Number of people with asymptomatic virus 
carriage was increasing till 2001 and has been slowly decreasing since then. There is 
no data about hepatitis C prevalence in Russia. Expected economic burden was cal-
culated on the basis of several assumptions: 1) only new cases of chronic hepatitis C 
are treated; 2) all new cases of acute hepatitis C are hospitalized, all new cases of 
chronic hepatitis C get hospital treatment ﬁ rst, then out-patient treatment; 3) and only 
15 % of all patients with chronic hepatitis C receive treatment with pegylated inter-
ferons and ribavirin reimbursed from national health care system. CONCLUSIONS: 
Based on these assumptions expected economic burden of hepatitis C infection in 
Russian Federation is about c0,16 million.
PIN20
PSEUDOMONAS AERUGINOSA RELATED ECONOMIC BURDEN 
STRATIFIED BY COMORBIDITY IN CYSTIC FIBROSIS PATIENTS
Sansgiry S1, Joish V2, Boklage S2, Goyal RK1, Seal B2, Sethi S3
1University of Houston, Houston, TX, USA; 2Bayer, Wayne, NJ, USA, 3University at Buffalo, 
SUNY, Buffalo, NY, USA
OBJECTIVES: To determine if the average cost of medical care among cystic ﬁ brosis 
(CF) patients post Pseudomonas aeruginosa (PA) infection is different for those with 
underlying comorbid conditions. METHODS: MarketScan claims database which 
captures person-speciﬁ c direct medical utilization, expenditures, and enrollment from 
approximately 150 payers was used to conduct a retrospective cross-sectional study. 
CF subjects with an initial claim for a PA infection were identiﬁ ed using international 
classiﬁ cation of diseases diagnosis codes of 277.0 and 482.1, respectively. Demo-
graphic information from administrative claims and health care utilization and costs 
from medical and pharmacy claims were extracted for 12 months post initial PA claim. 
All resource use and costs were annualized and compared among subjects with comor-
bidity and the overall sample using SAS version 9.2. RESULTS: Of the 347 CF subjects 
with PA infection that met the study criteria, 79% had multiple co-morbidities, 67% 
had pancreatic insufﬁ ciency, followed by chronic sinusitis (19%), CF-related diabetes 
(13%), bronchiectasis (7%), and osteoporosis (5%). Subjects had a mean age of 20 
years (SD 15.4) and 47.8% were females. As compared to an average CF subject, 
those with multiple co-morbidities had signiﬁ cantly higher (P < .05) overall pharmacy 
claims (mean 39 vs. 44) and cost (mean $20,673 vs. $24,121, median $17,121 vs. 
$22,344). Overall cost in subjects with CF-related diabetes (mean = $66,364 and 
median = $60,759) and osteoporosis (mean = $88,703 and median = $55,686) was 
signiﬁ cantly (P < 0.05) greater as compared to an average CF subject (mean = $51,821 
and median = $36,046). Among CF-related diabetic subjects and osteoporosis subjects, 
signiﬁ cantly (P < 0.05) higher outpatient visits and pharmacy claims and higher 
inpatient costs contributed to overall increase in health care costs compared to the 
average CF subject. CONCLUSIONS: Overall post-PA infection medical care costs 
were higher in comorbid cohorts compared to the overall CF sample. Future research 
needs to determine cost-effectiveness of PA infection treatment for among these comor-
bid conditions.
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EMPIRIC ANTIBIOTIC PRRESCRIBING IN SUBJECTS WITH INFLUENZA 
IN A UNITED STATES COMMERCIALLY INSURED POPULATION
Misurski DA1, Lipson D2, Changolkar AK1
1GlaxoSmithKline, Philadelphia, PA, USA; 2GlaxoSmithKline, King of Prussia, PA, USA
OBJECTIVES: To evaluate empiric antibiotic prescribing and associated costs in com-
mercially insured members with seasonal inﬂ uenza. METHODS: This retrospective 
analysis was conducted using Impact National Benchmark Database pharmacy, 
medical, and conﬁ nement claim data (01/01/2004 through 12/31/2009). The index 
date was deﬁ ned as the ﬁ rst inﬂ uenza (ICD-9:487.xx) claim, within the intake period 
(01/01/2005 through 11/30/2009). Subjects had continuous eligibility for ≥12 months 
prior to and one month after the index date. We used the ﬁ rst inﬂ uenza event only. 
Subjects with a pre-index diagnosis requiring antibiotic treatment were excluded. 
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Inﬂ uenza subjects with an antiviral claim within one day pre- and one day post-index 
and/or an antibiotic claim within three days pre- and three days post-index were 
identiﬁ ed. Subjects with a secondary respiratory infection within the two week post-
index period were identiﬁ ed via ICD-9 codes. RESULTS: The study cohort included 
270,057 members with inﬂ uenza (51.8% male; mean age 31.6 years). Antibiotics were 
prescribed in 63,358 (23.5%) of subjects (42,374 [15.7%] received an antibiotic only; 
20,984 [7.8%] received both an antiviral and an antibiotic). The majority of subjects 
with inﬂ uenza (157,447 [58.3%]) did not receive an antiviral. Among subjects receiv-
ing antibiotic treatment, 98.9% did not have a follow-up coded respiratory bacterial 
infection within two weeks. The mean antibiotic costs were $66.15 and $42.71 for 
subjects with and without a secondary bacterial respiratory infection, respectively. 
Antibiotic usage in inﬂ uenza subjects without a secondary bacterial respiratory infec-
tion accounted for approximately $2.7M (2009 US$). CONCLUSIONS: Almost all 
subjects with inﬂ uenza receiving antibiotic treatment did not have a secondary bacte-
rial respiratory condition. The cost associated with the empiric prescribing of antibiot-
ics was considerable. Furthermore, over half the subjects with inﬂ uenza did not receive 
antiviral therapy. As our study only allowed for one case per subject the total cost 
associated with empiric antibiotic prescribing in subjects with inﬂ uenza is likely an 
underestimate.
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A NOVEL APPROACH FOR ESTIMATING THE VALUE OF ENTECAVIR 
THERAPY FOR NUCLEOSIDE-NAÏVE CHRONIC HEPATITIS B PATIENTS 
IN SPAIN
Ramirez de Arellano A1, Fernandez-Rodriguez C2, Andrade R3, Clemente G4, Sola R5, 
Wells J6, Rentero P1
1Bristol-Myers Squibb Iberia, Madrid, Spain; 2Hospital Fundación Alcorcón, Madrid, Spain; 
3Hospital Virgen de la Victoria, Malaga, Spain; 4General Hospital Gregorio Marañon, Madrid, 
Spain; 5Hospital del Mar (IMIM), Barcelona, Spain; 6Monitor Group, London, UK
OBJECTIVES: Prescribers, payers and health care decision-makers operating in 
diverse health care settings are increasingly examining the value of innovative treat-
ments. The analysis aims at estimating the relative value of the two preferred ﬁ rst-line 
oral antiviral treatment options for chronic hepatitis B (CHB) according to the EASL 
guidelines: entecavir (ETV) and tenofovir (TDF) from a Spanish payer’s perspective. 
METHODS: Hepatitis B disease was simulated using a health-state transition model 
with disease-states deﬁ ned as mild disease (Ishak F0/F1), ﬁ brosis (F2–F4) and advanced 
ﬁ brosis/cirrhosis (>F4), and complicated disease-states (decompensated cirrhosis, 
hepatocellular carcinoma, liver transplant and death) based on available natural 
history data. The value of treatment-speciﬁ c attributes on disease progression/regres-
sion was estimated from clinical practice data in real world settings in terms of lifetime 
events and costs avoided. Treatment attributes included: additional testing require-
ments at treatment initiation and required renal function monitoring; adverse events 
per product labelling; reversal of ﬁ brosis; and treatment intensiﬁ cation in case of 
suboptimal viral suppression to avoid potential resistance. a 5-year treatment duration 
was assumed. Primary model output is the estimated cost avoided per-patient per day 
of treatment, associated with the clinical attributes of ETV compared to TDF in the 
treatment of nucleoside-naïve HBeAg-positive and -negative CHB patients. RESULTS: 
The daily cost of antiviral therapy for a CHB patient was estimated at c13.2 for ETV 
compared to c9.6 with TDF. Lifetime treatment cost avoided due to ETV’s clinical 
attributes was quantiﬁ ed at c3.6 [95% conﬁ dence: interval: 2, 5.2] per day of therapy. 
CONCLUSIONS: Estimating total treatment cost-avoidance associated with speciﬁ c 
clinical attributes is a novel approach in assessing the value of treatment options. ETV 
exhibits the characteristics of a favourable CHB treatment option, which directly 
translates into economic and therapeutic added value.
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DIFFERENTIAL PRICING POLICY AND ITS IMPACT ON TREAMENT 
COSTS OF VISCERAL LEISHMANIASIS IN THE BRAZILIAN PUBLIC 
HEALTH SYSTEM
Marinho DS1, Romero CNP1, Cechinel MP2, Martins EV1, Morel CM1
1Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; 2Brazilian Ministry of Health, Brasília, Brazil
BACKGROUND: Visceral leishmaniasis (VL) (“Kalazar”) is an important public 
health issue in Brazil. The guidelines of Brazilian Ministry of Health set up pentavalent 
antimony as the ﬁ rst line treatment, and amphotericin (deoxicolate and liposomal) as 
the second line treatment of VL. There are evidences that liposomal amphotericin (LA) 
and amphotericin deoxicolate (AD) present similiar efﬁ cacy, but LA has a better safety 
proﬁ le. Unfortunately, its price has been the principal barrier to its usage by public 
health system. OBJECTIVES: To evaluate the impact of differential pricing policy of 
LA in the Brazilian public health system. METHODS: The global amount spent on 
medicines from 2007 to 2009 by the Ministry of Health on the different types of 
treatment was retrieved from the Brazilian sanitary surveillance system. The following 
associated costs were also analyzed: hospital care and professional services; laborato-
rial tests (potassium, urea, creatinine and transaminases); and loss of working days 
(average daily income). This information allowed us to perform the cost analysis of 
the different therapeutic options. RESULTS: The differential pricing policy for LA 
implemented in 2008 allowed a cost reduction of 76.8% (from US$5.881 to US$590 
per treatment) enabling the Ministry of Health to double the number of patients 
treated with LA. The associated costs of hospitalization and loss of productivity by 
patients are higher with AD than with LA, but the total cost of LA treatment (medica-
tion + associated costs) is still 11.3% to 27% higher. CONCLUSIONS: In a societal 
perspective it was shown that a substantial price reduction of a safer drug enhanced 
its use and distribution by the Ministry of Health. It became also evident that the 
policy of differential pricing is an effective way to promote access to an efﬁ cient and 
safer treatment of VL, a disease that mainly affects the poor.
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IMPACT OF APPROPRIATE PRESCRIBING OF ANTIBIOTICS ON 
TREATMENT OUTCOMES, DAYS OF PATIENT HOSPITALIZATION AND 
COSTS OF ANTIBIOTIC TREATMENT IN HOSPITALS IN LESOTHO
Adorka MKB1, Serfontein JHP2, Lubbe MS2, Gous AGS3
1National University of Lesotho, Roma, Lesotho; 2North-West University, Potchefstroom, 
South Africa; 3University of Limpopo, Pretoria, South Africa
OBJECTIVES: The primary aim of this study was to determine the possible impact 
of appropriate prescribing of antibiotics on treatment outcomes, days of patient 
hospitalization and costs related to antibiotic treatment. METHODS: Data from case 
notes of all inpatients on antibiotic treatment and all antibiotic prescriptions from 
outpatient departments were collected from June 15 to July 15, 2006 at 5 government 
and mission hospitals in Lesotho. All prescriptions were classiﬁ ed into categories of 
appropriateness based on their conformities to criteria developed from principles of 
antibiotic prescribing. Analyses were further conducted to determine the possible 
impact that appropriate prescribing may have on treatment outcomes, days of patient 
hospitalization and costs of antibiotic treatments. RESULTS: A total of 307 inpatients 
and 867 outpatient prescriptions were assessed. Total frequencies of prescribed anti-
biotics were 584 and 1073 for inpatients and outpatients respectively. For inpatients 
antibiotics were most often prescribed for skin and soft tissue (31.7%) and respiratory 
tract (28.9%) infections. Outpatients received most antibiotics for respiratory tract 
(42.0%) and skin and soft tissue infection (21.9%) respectively. Of the 307 inpatient 
prescriptions 41.6% were appropriately written for either empiric treatment or pro-
phylaxis of infections while 57.1% did not conform to antibiotic prescribing princi-
ples. a majority (81.0%) of outpatient prescriptions were in line with the prescribing 
principles. Inpatient antibiotic prescribing patterns based on principles of antibiotic 
prescribing have had a positive impact on treatment outcomes, days of hospitalization 
and costs of antibiotic treatment. In outpatients prescribing of antibiotics based on 
principles of antibiotic prescribing failed to show any signiﬁ cant impact on costs of 
antibiotics. Due to geographical challenges the outcome for treatment could not be 
determined for outpatients. CONCLUSIONS: Rational prescribing had a positive 
impact on treatment outcomes.
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SEASONAL INFLUENZA VACCINATION OF HEALTHY, WORKING-AGE 
ADULTS: A SYSTEMATIC REVIEW OF ECONOMIC INVESTIGATIONS
Gatwood J1, Meltzer M2, Messonnier M2, Prosser LA1
1University of Michigan, Ann Arbor, MI, USA; 2Centers for Disease Control and Prevention, 
Atlanta, GA, USA
OBJECTIVES: To assess cost-beneﬁ t and cost-effectiveness studies examining seasonal 
inﬂ uenza vaccination in the healthy, working-age population of the United States (US). 
METHODS: A systematic review of economic evaluations investigating the cost-
beneﬁ t or cost-effectiveness of vaccinating healthy adults was conducted on articles 
published between January 1990 and January 2010. Studies considered for inclusion 
in this review were identiﬁ ed using Medline, Embase, Econlit, and Google Scholar (n 
= 11). The source and appropriateness of parameters (epidemiological data, probabili-
ties, and costs), the designs employed, and the sufﬁ ciency of sensitivity analysis were 
considered during the review. RESULTS: Seven studies were identiﬁ ed as appropriate 
for this review. Key inputs of the selected studies included inﬂ uenza or ILI attack rates, 
outpatient visits averted, total vaccination costs, and lost workdays. All studies were 
conducted in the US and from the societal perspective; three were randomized, clinical 
trials and the remaining four constructed economic simulation models to compare 
vaccination to antivirals or no intervention. Results ranged from net savings of $69.19 
to net costs of $85.89 per vaccination (4 studies) and from $103.95 to $1004.85 per 
episode of inﬂ uenza averted (1 study). Only 2 studies reported cost-effectiveness ratios; 
these ranged from $6,930 to $50,510 per quality-adjusted life-year gained. Nearly all 
of the studies conducted sensitivity analysis; results were most sensitive to variation 
in wage rates, levels of worker productivity, the cost and effectiveness of vaccination, 
and the rate of illness. CONCLUSIONS: This systematic review found that seasonal 
inﬂ uenza vaccination of healthy, working-age adults is generally not cost saving, 
requiring an investment to generate health beneﬁ ts. The decision to vaccinate such a 
group will depend upon the societal and payer valuation of those beneﬁ ts.
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EARLY VS. LATE DETECTION OF HIV IN UK: COST CONSEQUENCE 
STUDY
Mesa OA1, Mason N1, Zah V2
1Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, Middlesex, UK; 2ZRx Outcomes 
Research Inc, Toronto, ON, Canada
OBJECTIVES: Identifying budgetary implications and opportunities for earlier detec-
tion versus late detection of HIV (CD4 cell count less than 200/μl) in the 1 through 
5 year term following diagnosis. In 2009, there were 90,468 HIV positive individuals 
not accounting for unreported HIV positive cases (in 2008, estimated additional 24%). 
Late detection HIV patients account for 32% from the total. METHODS: A literature 
review was conducted using MEDLINE, Cochrane Library, EMBASE and CRD for 
guidelines and clinical trials published 1995–2010 in UK, England, Scotland, Wales, 
Northern Ireland, USA, Canada, Australia, Norway and EU-26. We extrapolated UK 
